SCHEMBL24965950

SCHEMBL24965950

CC(C)(C)OC(=O)CC[C@H](NC(=O)OC(C)(C)C)C(=O)NCCN

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CTSK P43235 8/20 0.50
CTSS P25774 8/20 0.50
CAPN1 P07384 1/20 0.47
CA2 P00918 1/20 0.44
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
PLK1 P53350 2/20 0.42
ITGB3 P05106 6/20 0.41
ITGA2B P08514 6/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19401696 1.00 CTSK (0.50) CTSKCTSSCAPN1CA2CTSL
SCHEMBL18291443 0.89 CTSS (0.45) CTSKCTSSCAPN1CA2CTSL
SCHEMBL13567291 0.88 CTSS (0.51) CTSKCTSSCAPN1CA2CTSL
SCHEMBL24984812 0.87 CTSS (0.44) CTSKCTSSCAPN1CA2CTSL
SCHEMBL13921014 0.86 CTSK (0.50) CTSKCTSSCAPN1CA2CTSL
SCHEMBL13921025 0.86 CTSK (0.50) CTSKCTSSCAPN1CA2CTSL
SCHEMBL23974449 0.86 CTSK (0.51) CTSKCTSSCAPN1CA2ITGB3
SCHEMBL21973062 0.86 CAPN1 (0.37) CTSKCTSSCAPN1CA2PLK1
SCHEMBL17870152 0.85 CTSK (0.49) CTSKCTSSCAPN1CA2CTSL
SCHEMBL13934348 0.85 CTSK (0.60) CTSKCTSSCAPN1CTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023001223-A1 COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) 2023-01-26 WO disclosed
WO-2023001224-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL CANCERS SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) 2023-01-26 WO disclosed